Can a new drug combo reset the immune system to beat relapsed leukemia?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1.Patients with a confirmed diagnosis of relapsed or refractory acute myeloid leukemia (AML) based on bone marrow morphology, immunophenotyping, and cytogenetics. * 2\. Patients who are planned to undergo allogeneic hematopoietic stem cell transplantation, including HLA-matched or HLA-mismatched related allogeneic transplantation, as well as unrelated donor transplantation. * 3\. Age between 18 and 65 years, inclusive, regardless of gender. * 4\. Eastern Cooperative Oncology Group performance status (ECOG) of 0-2. * 5\. Written informed consent must be obtained prior to the initiation of any study-related procedures. For patients aged 18 years or older, the consent form may be signed by the patient or by a direct relative. Should the patient's own signature be judged to be potentially harmful to their clinical care, consent may instead be given by a legal guardian or a direct relative. Exclusion Criteria: * 1\. Uncontrolled active infection (bacterial, fungal, or viral). * 2\. Known positive serology for human immunodeficiency virus (HIV) or active hepatitis C virus (HCV). * 3\. Psychiatric disorders or other medical conditions that preclude compliance with the study treatment and monitoring requirements. * 4\. Pregnant patients, or patients who are unwilling or unable to use adequate contraceptive measures during the treatment period. * 5\. Prior hematopoietic stem cell transplantation. * 6\. Active cardiac disease, defined as one or more of the following: History of uncontrolled or symptomatic angina pectoris; Myocardial infarction within 6 months prior to study enrollment; History of arrhythmia requiring medication or clinically significant symptomatic arrhythmia; Uncontrolled or symptomatic congestive heart failure (\> New York Heart Association \[NYHA\] class 2); Ejection fraction below the lower limit of normal; Previous coronary angioplasty or stent implantation. * 7\. Severe hepatic impairment, defined as liver function parameters (ALT, TBIL) \> 3 × upper limit of normal (ULN); or severe renal impairment, defined as serum creatinine (Cr) \> 2 × ULN, or 24-hour urine creatinine clearance \< 50 mL/min; or any other condition that, in the investigator's opinion, renders the patient unsuitable for treatment with the study drug. * 8\. Any other condition that, in the investigator's opinion, makes the patient ineligible for study participation.